©2024 Stanford Medicine
Blood Pressure Lowering in Acute Stroke Trial (BLAST)
Not Recruiting
Trial ID: NCT00627991
Purpose
Patients who are suffering from a stroke often present to the hospital with elevated blood
pressure. Elevated blood pressure in the setting of stroke increases the risk of brain
swelling or bleeding into the brain. Even so, there has been concern about lowering the blood
pressure with medications because the newly injured parts of the brain may not get the blood
flow they need, thereby worsening the damage from the initial stroke. We hope to demonstrate
that the drug valsartan can be used safely and modestly to lower blood pressure in acute
stroke patients, without having a detrimental effect on brain blood flow or neurologic
status. Novel MRI techniques to measure brain blood flow will be used in conjunction with
clinical scales to demonstrate safety.
Official Title
The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Effects on Cerebral Blood Flow.
Stanford Investigator(s)
Gregory W. Albers, MD
Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
1. Men and non-pregnant women over age 18 who have had an acute ischemic stroke referable
to the anterior circulation, as diagnosed by one of more of the following: clinical
judgment, head CT, and/or MR imaging [i.e. a positive diffusion-weighted imaging (DWI)
abnormality].
2. Clinical syndrome not likely to represent transient ischemic attack (TIA) or other
non-stroke etiology
3. Patient must be neurologically stable at the time of first MRI scan (i.e. stable NIH
Stroke Scale score).
4. Initial MRI scan obtainable within 48 hours of symptom onset.
5. A pre-existing diagnosis of hypertension, either treated or untreated.
6. Average of two mean arterial blood pressures (separated by at least five minutes) at
time of enrollment.
Exclusion Criteria:
1. Patients who have taken an angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB) within seven (7) days of admission.
2. Patients who received intravenous or intra-arterial r-TPA for their current symptoms,
or those who underwent mechanical thrombolysis.
3. Patients with hemorrhagic strokes, as seen on the initial head CT.
4. Patients with stroke-like symptoms, but no demonstrable lesion on DWI, or a DWI lesion
< 2 cm in diameter (greatest dimension).
5. Patients with high-grade (>70%) internal carotid artery stenosis or occlusion
ipsilateral to the current stroke.
6. Patients with high-grade aortic or mitral stenosis.
7. Patients with a previous adverse reaction to valsartan or other ARBs.
8. Patients with contraindications for MRI, including pacemakers, claustrophobia, or
severe obesity.
9. Patients who are medically unstable for MR imaging, as determined by the treating
team.
10. Patients with a severe co-existing disease that may interfere with the conduct of the
study.
11. Patients receiving investigational drug therapies.
12. Informed consent cannot be obtained from the patient or an appropriate surrogate.
Intervention(s):
drug: Valsartan
drug: Valsartan
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305